Kymera Therapeutics, Inc. has outlined its key objectives for 2025, emphasizing its strategy to advance a portfolio of oral immunology programs. The company is currently making progress with several clinical trials and has announced the initiation of new trials and the disclosure of a new program.
In terms of specific developments, the company's KT-621 (Stat6) phase 1 healthy volunteer trial is ongoing, with data expected in the second quarter of 2025. Plans are in place to initiate a KT-621 phase 1b trial in atopic dermatitis (AD) patients in the same quarter, with data expected in the fourth quarter of 2025. Furthermore, Kymera plans to initiate parallel phase 2b trials in AD and asthma in late 2025 and early 2026, respectively.
Additionally, the company's KT-295 (Tyk2) is set to advance into phase 1 testing in the second quarter of 2025, with data expected in late 2025. The KT-474/SAR444656 (Irak4) phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD are ongoing, with completion expected in the first half of 2026 and mid-2026, respectively.
Kymera also plans to disclose a novel oral immunology program with a first-in-class development candidate in the first half of 2025 and to initiate clinical testing in early 2026.
As of the announcement, Kymera Therapeutics, Inc. is well-capitalized with $8501 million in cash and runway into mid-2027. The company aims to present its 2025 outlook at the J.P. Morgan Annual Healthcare Conference.
Kymera Therapeutics, Inc.'s President and CEO, Nello Mainolfi, Ph.D., expressed optimism about the year ahead, highlighting the company's vision to leverage the power of targeted protein degradation to deliver oral drugs with biologics-like activity, potentially revolutionizing the treatment of many inflammatory diseases with significant unmet needs.
The company also provided specific details about its pipeline, including upcoming milestones for its Stat6 degrader program (KT-621), Tyk2 degrader program (KT-295), and Irak4 degrader program (KT-474/SAR444656). Moreover, Kymera plans to announce the next immunology program, a first-in-class development candidate addressing an undrugged transcription factor, in the first half of 2025.
This strategic outline from Kymera Therapeutics, Inc. demonstrates the company's commitment to advancing its clinical pipeline and developing innovative oral immunology medicines to address areas of significant need. As a result of these announcements, the company's shares have moved 7.8% on the market, and are now trading at a price of $40.12. For more information, read the company's full 8-K submission here.
